All Drug Targets articles – Page 17
-
WebinarAdvancing ADC Development: End-to-End Solutions from Design to Characterization
Dr. Francisca Neethling from Eurofins Discovery explores the comprehensive process of ADC development, covering payload linker design, optimization, and the bioanalytical and functional characterization of ADC molecules.
-
NewsNew approach targets VHR enzyme for sepsis treatment
A new study reveals a promising approach to sepsis treatment by targeting the VHR enzyme using fragment-based drug discovery. This innovative method could lead to more effective therapies for sepsis and other immune-related conditions.
-
NewsDrug OLX-07010 shows promise in treating tau diseases
OLX-07010, a new drug from Oligomerix, shows potential in reducing tau protein tangles, a key factor in Alzheimer's and other tau-related diseases. Early studies suggest it could be a breakthrough in targeting tau aggregation and improving brain function.
-
NewsTract Bio identifies drug targets for oesophageal cancer
Tract Bio’s new research reveals key insights into the evolution of oesophageal adenocarcinoma (EAC) and identifies promising drug combinations for more effective treatment.
-
NewsNew research offers hope for high-grade glioma treatment
High-grade glioma, an aggressive brain cancer affecting both paediatric and adult patients, remains difficult to treat. A collaborative study from the University of Michigan, Dana-Farber Cancer Institute, and the Medical University of Vienna reveals a promising new treatment approach.
-
WebinarSolving the AOC puzzle: Strategies for chemistry, manufacturing and regulatory success
Watch our webinar with Abzena’s experts to explore practical solutions for overcoming chemistry, manufacturing and regulatory challenges in antibody-oligonucleotide conjugate (AOC) development, enabling progress for previously untreatable diseases.
-
WebinarReprogramming immunity: designing smarter checkpoint receptor agonists
Join Dr Daniela Cipolletta from Seismic Therapeutic to discover how FcγRIIb clustering enabled the discovery of S-4321, a low-affinity PD-1 agonist that restores immune balance by engaging multiple inhibitory pathways.
-
ArticleRefining and targeting exatecan with ADC technology
DTR speaks with Dr Patrick van Berkel at ADC Therapeutics to discuss how the company is transforming exatecan delivery to achieve better health outcomes.
-
NewsNew AI algorithm searches 10 sextillion drug candidates
Scientists have developed an AI algorithm capable of searching through 10 sextillion potential drug molecules, a feat previously considered impossible. This method could significantly speed up drug discovery and the development of new treatments.
-
NewsRare diseases, big advances: how research is powering a new era of treatments
This Friday, February 28, marks Rare Disease Day 2025, a global initiative raising awareness for the 300 million people living with rare conditions. Dr David Reynolds, CEO of LoQus23 Therapeutics, explores how advancements in rare disease research are driving the development of new treatments.
-
NewsGinger-based compound targets inflammation in IBD
Researchers at the University of Toronto have discovered a compound in ginger, furanodienone (FDN), that interacts with the pregnane X receptor to reduce inflammation in the colon. This finding suggests FDN could be an effective, natural treatment for inflammatory bowel disease (IBD).
-
NewsStudy identifies new genetic targets for neuropsychiatric diseases
Scientists identify thousands of novel enhancers linked to neuronal differentiation and neuropsychiatric disorders, offering new pathways for drug discovery and potential therapeutic targets.
-
NewsStudy reveals 58 targets for heart failure drug development
A new study has identified novel drug targets for heart failure, focusing on two major types of the condition. These findings could lead to more effective, targeted treatments for both heart failure subtypes.
-
NewsScientists identify key protein fuelling autoimmune attacks
Mass General Brigham researchers found granzyme K (GZMK) drives inflammation in autoimmune diseases, opening new possibilities for targeted treatments.
-
NewsAzenta's BioArc Ultra powers UK research
UK Biocentre has significantly expanded its sample storage capacity with the addition of Azenta's BioArc Ultra, adding space for 16 million more samples to support vital health research.
-
NewsRestoring the gut: VE303's strategy for C. diff relief
A new publication in Nature Medicine highlights the potential of VE303 for preventing recurrent C. difficile infection, detailing its impact on the gut microbiome and immune response.
-
ArticleNew study explores safer antidepressants for pregnant women
A new study suggests that targeting serotonin in the gut, rather than the brain, could lead to antidepressants with fewer side effects.
-
NewsUVA’s computer models target antibiotics to combat resistance
Researchers at the University of Virginia School of Medicine have developed computer models to create more targeted antibiotics. This approach aims to fight antibiotic resistance by focusing on specific bacteria in different parts of the body, reducing the reliance on broad-spectrum antibiotics.
-
WebinarThe rise of organoids: a new era in drug discovery
This webinar covers how organoids are reshaping drug discovery by providing more accurate models for disease research and drug testing, offering new solutions to long-standing challenges in the industry.
-
NewsCollaboration aims to advance automated insulin technology for diabetes
UVA Center for Diabetes Technology and Tandem Diabetes Care partner to advance automated insulin delivery systems for diabetes management.